Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) Versus Treatment Choice in Adults With Previously Treated Acute Myeloid Leukemia

Multicenter, randomized, open-label, parallel-group study of guadecitabine vs treatment choice (TC). Participants will be randomly assigned in a 1:1 ratio to either guadecitabine or TC. TC options include the 8 high or low intensity, locally available regimens below; or Best supportive Care (BSC) alone:

• High intensity (intermediate or high dose cytarabine [HiDAC]; mitoxantrone, etoposide, and cytarabine [MEC]; or fludarabine, cytarabine, granulocyte colony stimulating factor [G-CSF], +/- idarubicin [FLAG/FLAG-Ida]).
• Low intensity (low dose cytarabine [LDAC], decitabine, or azacitidine).
• BSC.

Study Overview

• Status: Completed
• Conditions: Acute Myeloid Leukemia
• Intervention / Treatment: Drug: guadecitabine; Drug: Treatment Choice (TC)

Detailed Description

This Phase 3, randomized, open-label, parallel-group multicenter study of the efficacy and safety of guadecitabine in adults with previously treated acute myeloid leukemia (AML) will be conducted in approximately 20 countries. There will be a 14-day screening period, a treatment period, a safety follow-up visit, and a long-term follow-up period. The study is expected to last approximately 2 years. Duration of individual participant participation will vary, and participants may continue to receive treatment for as long as they continue to benefit.

Approximately 404 participants from approximately 100 study centers will be randomly assigned to either guadecitabine or treatment choice (TC) in a 1:1 ratio (approximately 202 participants per group). TC is as follows:

• High intensity: intermediate or high dose cytarabine (HiDAC); mitoxantrone, etoposide, and cytarabine (MEC); or fludarabine, cytarabine, G-CSF, +/- idarubicin (FLAG/FLAG-Ida).
• Low intensity: low dose cytarabine (LDAC), decitabine, or azacitidine.
• Best Supportive Care (BSC).

Guadecitabine will be given subcutaneous (SC) at a dose of 60 microgram per meter square (mg/m^2) in 28-day cycles. In Cycle 1, guadecitabine will be given for 10 days on Days 1-5 and Days 8-12. Cycle 2 will be either the 5-day regimen (Days 1-5) or 10-day regimen (Days 1-5 and 8-12) based on assessment of disease response and hematologic recovery at the end of Cycle 1. In subsequent cycles, guadecitabine treatment will be for 5 days only (Days 1-5).

• Study Type: Interventional
• Enrollment (Actual): 302
• Phase: Phase 3

Contacts and Locations

Study Locations

• Belgium
  • Brugge, Belgium, 8000
    • AZ Sint-Jan Brugge-Oostende AV
  • Brussels, Belgium, 1200
    • Cliniques universitaires Saint-Luc
  • Gent, Belgium, 9000
    • Universitair Ziekenhuis Gent
• Canada
  • Montreal, Canada, H1T 2M4
    • Hôpital Maisonneuve Rosemont
  • Alberta
    • Calgary, Alberta, Canada, T2N 4N2
      • Tom Baker Cancer Centre
    • Edmonton, Alberta, Canada, T6G 2V2
      • University of Alberta Hospital
  • Ontario
    • Toronto, Ontario, Canada, M5G 2C1
      • Princess Margaret Cancer Centre
  • Quebec
    • Montreal, Quebec, Canada, H4A 3J1
      • McGill University Health Centre
• Denmark
  • Aarhus C, Denmark, 8000
    • Aarhus University Hospital
  • Copenhagen, Denmark, 2100
    • Rigshospitalet
• France
  • Bayonne, France, 64100
    • Centre Hospitalier de la Cote Basque
  • Marseille, France, 13385
    • Hôpital de la Conception
  • Montpellier, France, 34295
    • CHRU Montpellier - Saint Eloi
  • Mulhouse, France, 68100
    • Groupe hospitalier de la région de Mulhouse et Sud Alsace
  • Paris, France, 75475
    • Hôpital Saint-Louis
  • Pessac, France, 33604
    • CHU Hopitaux de Bordeaux - Hôpital Haut-Lévêque
  • Pierre Bénite, France, 69310
    • Centre hospitalier Lyon-Sud
  • Rouen cedex 1, France, 76038
    • Centre Henri Becquerel
  • Toulouse, France, 31059
    • Institut Universitaire du Cancer de Toulouse - Oncopole
• Germany
  • Braunschweig, Germany, 38114
    • Städtisches Klinikum Braunschweig gGmbH
  • Düsseldorf, Germany, 40479
    • Marien Hospital Dusseldorf GMBH
  • Halle, Germany, 6120
    • Universitatsklinikum Halle (Saale)
  • Kiel, Germany, 24105
    • Universitätsklinikum Schleswig-Holstein
  • Mannheim, Germany
    • Medizinischen Fakultät Mannheim der Universität Heidelberg
  • Muenchen, Germany, 81377
    • Klinikum der Universität München
  • Ulm, Germany, 89081
    • Universitatsklinikum Ulm
  • Sachsen
    • Leipzig, Sachsen, Germany, 4103
      • Universitätsklinikum Leipzig
• Hungary
  • Budapest, Hungary, 1083
    • SE ÁOK I. sz. Belgyógyászati Klinika
  • Debrecen, Hungary, 4032
    • Debreceni Egyetem Klinikai Kozpont
  • Kaposvar, Hungary, 7400
    • Somogy Megyei Kaposi Mór Oktató Kórház
  • Pécs, Hungary
    • Pécsi Tudományegyetem Klinikai Központ
  • Szeged, Hungary, 6725
    • Szegedi Tudomanyegyetem
• Italy
  • Genova, Italy, 16132
    • IRCCS AOU San Martino - IST
  • Milano, Italy, 20122
    • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
  • Milano, Italy, 20132
    • Ospedale San Raffaele - Milano
  • Napoli, Italy, 80131
    • A.O.R.N. "A. Cardarelli"
  • Udine, Italy, 33100
    • A.S.U Integrata di Udine - Presidio Ospedaliero Santa Maria della Misericordia
• Japan
  • Akita-shi, Japan, 010-8543
    • Akita University Hospital
  • Fukuyama-Shi, Japan, 720-0001
    • Chugoku Central Hospital
  • Isehara-shi, Japan, 259-1193
    • Tokai University Hospital
  • Kawagoe-Shi, Japan, 350-8550
    • Saitama Medical Center
  • Kobe-shi, Japan, 650-0047
    • Kobe City Medical Center General Hospital
  • Kyoto-shi, Japan, 602-8026
    • Japanese Red Cross Kyoto Daini Hospital
  • Kyoto-shi, Japan, 602-8566
    • University Hospital, Kyoto Prefectural University of Medicine
  • Maebashi-shi, Japan, 371-0821
    • Gunmaken Saiseikai Maebashi Hospital
  • Nagasaki-Shi, Japan, 852-8511
    • The Japanese Red Cross Nagasaki Genbaku Hospital
  • Nagasaki-shi, Japan, 852-8501
    • Nagasaki University Hospital
  • Osakasayama-Shi, Japan, 589-8511
    • Kindai University Hospital
  • Saga-shi, Japan, 849-8501
    • Saga University Hospital
  • Shinagawa-Ku, Japan, 141-8625
    • NTT Medical Center Tokyo
  • Shizuoka, Japan, 411-8777
    • Shizuoka Cancer Center
  • Tachikawa-Shi, Japan, 190-0014
    • National Hospital Organization Disaster Medical Center
  • Yamagata-Shi, Japan, 990-9585
    • Yamagata University Hospital
  • Yoshida-Gun, Japan, 910-1193
    • University of Fukui Hospital
• Korea, Republic of
  • Busan, Korea, Republic of, 49241
    • Pusan National University Hospital
  • Seoul, Korea, Republic of, 3080
    • Seoul National University Hospital
  • Seoul, Korea, Republic of, 6351
    • Samsung Medical Center
  • Seoul, Korea, Republic of, 5505
    • Asan Medical Center
  • Seoul, Korea, Republic of, 3722
    • Severance Hospital
  • Seoul, Korea, Republic of, 6591
    • The Catholic University of Korea, Seoul St. Mary's Hospital
  • Ulsan, Korea, Republic of, 44033
    • Ulsan University Hospital (UUH)
• Poland
  • Warszawa, Poland, 02-776
    • Instytut Hematologii i Transfuzjologi
• Spain
  • Barcelona, Spain, 8036
    • Hospital Clinic de Barcelona
  • Barcelona, Spain, 8041
    • Hospital de La Santa Creu I Sant Pau
  • Barcelona, Spain, 8907
    • Hospital Duran I Reynals
  • Barcelona, Spain
    • Vall d'Hebron Institut d'Oncologia
  • Cáceres, Spain, 10003
    • Hospital San Pedro de Alcántara
  • Córdoba, Spain, 14004
    • Hospital Universitario Reina Sofia
  • Madrid, Spain, 28007
    • Hospital General Universitario Gregorio Maranon
  • Oviedo, Spain, 33011
    • Hospital Universitario Central de Asturias
  • Sevilla, Spain, 41013
    • Hospital Universitario Virgen del Rocío
  • Valencia, Spain, 46026
    • Hospital Universitari I Politecnic La Fe
  • Valencia, Spain, 46017
    • Hospital Universitario Dr. Peset
• Sweden
  • Göteborg, Sweden, 413 45
    • Sahlgrenska University Hospital
• Ukraine
  • Khmelnytskyi, Ukraine, 29000
    • Khmelnytskyi Regional Hospital
  • Poltava, Ukraine, 36011
    • Poltava Regional Clinical Hospital named after M. V. Sklifosovskoho
• United Kingdom
  • Birmingham, United Kingdom, B9 5SS
    • Heart of England NHS Foundation Trust - Heartlands Hospital
  • Bristol, United Kingdom, BS2 8ED
    • University Hospitals Bristol NHS Foundation Trust - Bristol Haematology and Oncology Centre
  • Canterbury, United Kingdom, CT1 3NG
    • East Kent Hospitals University NHS Foundation Trust - Kent and Canterbury Hospital
  • Leeds, United Kingdom, LS9 7TF
    • St. James's University Hospital
• United States
  • California
    • Los Angeles, California, United States, 90033
      • University of Southern California
  • Illinois
    • Chicago, Illinois, United States, 60637
      • The University of Chicago Medical Center
  • Indiana
    • Indianapolis, Indiana, United States, 46237
      • Franciscan Research Center
  • New Jersey
    • Hackensack, New Jersey, United States, 07601-1915
      • John Theurer Cancer Center at Hackensack University Medical Center
  • New Mexico
    • Albuquerque, New Mexico, United States, 87106
      • University of New Mexico School of Medicine
  • New York
    • Buffalo, New York, United States, 14263
      • Roswell Park Cancer Institute
    • New York, New York, United States, 10021
      • Weill Cornell Medical College
  • North Carolina
    • Durham, North Carolina, United States, 27710
      • Duke Cancer Institute
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73104-5418
      • University of Oklahoma Medical Center
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19104
      • Hospital of the University of Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19111-2433
      • Temple University Hospital
  • Tennessee
    • Nashville, Tennessee, United States, 37232
      • Vanderbilt University Medical Center
  • Texas
    • Dallas, Texas, United States, 75246
      • Baylor Research Institute
    • Houston, Texas, United States, 77030
      • MD Anderson Cancer Center
  • West Virginia
    • Morgantown, West Virginia, United States, 26506
      • West Virginia University Hospitals, Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Adult participants ≥18 years of age who are able to understand study procedures, comply with them, and provide written informed consent before any study-specific procedure.
2. History of cytologically or histologically confirmed diagnosis of AML (except acute promyelocytic leukemia) according to the 2008 World Health Organization (WHO) classification (bone marrow [BM] or peripheral blood [PB] blast counts ≥20%).
3. Performance status (Eastern Cooperative Oncology Group; ECOG) of 0-2.
4. Participants with AML previously treated with initial induction therapy using a standard intensive chemotherapy regimen, including cytarabine and an anthracycline, and who are refractory to initial induction (primary refractory) or in relapse after such initial induction with or without prior HCT.
5. Participants must have either PB or BM blasts ≥5% at time of randomization.
6. Creatinine clearance or glomerular filtration rate ≥30 mL/min as estimated by the Cockroft-Gault (C-G) or other medically acceptable formulas, such as MDRD (Modification of Diet in Renal Disease) or CKD-EPI (the Chronic Kidney Disease Epidemiology Collaboration).
7. Women of child-bearing potential must not be pregnant or breastfeeding and must have a negative pregnancy test at screening. Women of child-bearing potential and men with female partners of child-bearing potential must agree to practice 2 highly effective contraceptive measures of birth control and must agree not to become pregnant or father a child (a) while receiving treatment of guadecitabine, decitabine, or azacitidine and for at least 3 months after completing treatment and (b) while receiving treatment with high-intensity TC or LDAC and for at least 6 months after completing treatment.

Exclusion Criteria:

1. Known clinically active central nervous system (CNS) or extramedullary AML, except leukemia cutis.
2. Participants who are in first relapse after initial induction, if they had a response duration of >12 months from date when first response first documented or if they are good candidates for HCT.
3. BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
4. Second malignancy currently requiring active therapy, except breast or prostate cancer stable on or responding to endocrine therapy.
5. Grade 3 or higher Graft Versus Host Disease (GVHD), or GVHD on either a calcineurin inhibitor or prednisone more than 5 mg/day.
6. Prior treatment with guadecitabine for any indication, or more than 2 cycles of prior decitabine or azacitidine.
7. Hypersensitivity to decitabine, guadecitabine, or any of their excipients.
8. Treated with any investigational therapy within 2 weeks of the first dose of study treatment.
9. Total serum bilirubin >2.5 × upper limit of normal (ULN; except for participants with Gilbert's Syndrome for whom direct bilirubin is <2.5 × ULN), or liver cirrhosis, or chronic liver disease Child-Pugh Class B or C.
10. Known active human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. Inactive hepatitis carrier status or low viral hepatitis titer on antivirals is allowed.
11. Known significant mental illness or other condition such as active alcohol or other substance abuse or addiction that, in the opinion of the investigator, predisposes the participant to high risk of noncompliance with the protocol.
12. Refractory congestive heart failure unresponsive to medical treatment; active infection resistant to all antibiotics; or non-AML-associated pulmonary disease requiring >2 liters per minute (LPM) oxygen, or any other condition that puts the participant at an imminent risk of death.
13. Participants with high PB blasts >50% AND poor ECOG PS of 2.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Treatment Choice (TC); High intensity; Low intensity; Best supportive care (BSC).	Drug: Treatment Choice (TC); High intensity: intermediate or high dose cytarabine (HiDAC); mitoxantrone, etoposide, and cytarabine (MEC); or fludarabine, cytarabine, G-CSF, +/- idarubicin (FLAG/FLAG-Ida).; Low intensity: low dose cytarabine (LDAC), decitabine, or azacitidine.; Best Supportive Care (BSC).
Experimental: guadecitabine; Guadecitabine will be given SC at a dose of 60 mg/m^2 in 28-day cycles (delayed as necessary to allow blood count recovery).	Drug: guadecitabine; In Cycle 1, guadecitabine will be given for 10 days on Days 1-5 and Days 8-12. In Cycle 2, the guadecitabine dose will be 60 mg/m^2 for either 10 days (Days 1-5 and 8-12) or 5 days (Days 1-5 only) based on assessment of disease response, and hematological recovery by Day ≥28.; Other Names: SGI-110

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival	Overall survival is defined as number of days from day of randomization to date of death, regardless of cause.	From the date of randomization until the date of death, or approximately 34 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Event-Free Survival	Event-free survival is defined as number of days from randomization to earliest date of treatment discontinuation (for reasons other than initiation of hematopoietic cell transplant [HCT]), start of alternative anti-leukemia therapy (except HCT), or death.	From the date of randomization until the date of death, or approximately 38 months
Long-Term Survival	Survival rate at 1 year after randomization; participants were also followed to estimate 2-year survival rate.	Up to approximately 38 months
Number of Days Alive and Out of the Hospital (NDAOH)	Number of days participants alive and out of hospital during first 6 months of the study.	6 months
Transfusion Independence Rate	Number of participants without red blood cells (RBC) or platelet transfusion for any 8-week period after treatment divided by total number of participants in efficacy analysis.	Baseline up to approximately 38 months
Complete Response Rate	The Complete response (CR) rate based on modified International Working Group (IWG) 2003 AML Response Criteria was calculated as the number of participants with a best response of CR divided by the total number of participants included in the efficacy analysis. CR as per modified 2003 IWG AML Response Criteria is absolute neutrophil count (ANC) ≥1000/μL, platelets ≥100,000/μL, independence from red blood cells (RBC) and platelet transfusions over the past week, no leukemic blasts in peripheral blood and bone marrow should contain less than 5% blast cells.	Baseline to end of treatment, or approximately 38 months
Combined Complete Response and Complete Response With Partial Hematologic Recovery Rate	The combined CR and CR with partial hematologic recovery rate based on modified International Working Group (IWG) 2003 AML Response Criteria was calculated as number of participants with CR and CR with partial hematologic recovery divided by the total number of participants included in the efficacy analysis. CR as per modified 2003 IWG AML Response Criteria is absolute neutrophil count (ANC) ≥1000/μL, platelets ≥100,000/μL, independence from red blood cells (RBC) and platelet transfusions over the past week, no leukemic blasts in peripheral blood and bone marrow should contain less than 5% blast cells.	Baseline to end of treatment, or approximately 38 months
Composite Complete Response Rate	Composite complete response rate based on modified IWG 2003 AML Response Criteria defined as number of participants with best response of CR, CR with incomplete platelet recovery (CRp), or CR with incomplete blood count recovery (CRi) divided by total number of participants in efficacy analysis. CR as per modified 2003 IWG AML Response Criteria is ANC ≥1000/μL, platelets ≥100,000/μL, independence from RBC and platelet transfusions over the past week, no leukemic blasts in peripheral blood and bone marrow should contain less than 5% blast cells. CRp is defined as ANC ≥1000/μL, Platelets <100,000/μL, independence from RBC transfusions over the past week, no leukemic blasts and bone marrow should contain less than 5% blast cells. CRi is defined as ANC <1000/μL, no leukemic blasts and bone marrow should contain less than 5% blast cells.	Baseline to end of treatment, or approximately 38 months
Hematopoietic Cell Transplant (HCT) Rate	Number of participants who received HCT after randomization divided by total number of participants in efficacy analysis.	Baseline to long term follow-up or approximately 38 months
Duration of Complete Response (CR) + CR With Partial Hematologic Recovery (CRh)	The time from first CR or CRh to time of relapse (the date of the earliest of the following 3 events): relapse (defined as the earliest time point whereby BM assessment or PB assessment by the investigator indicate relapse/disease progression due to confirmed reappearance of leukemic blasts in PB or ≥5% leukemic blasts in BM, or clinical progression determined by the investigator),; start of alternative therapy (except HCT) or; death.	Baseline to end of treatment, or approximately 38 months
Change From Baseline in EuroQoL-5 Dimension 5 Level (EQ-5D-5L) Index Scores	Index score is calculated based on 5-level version of the EQ-5D descriptive system using the value set for England. The range of index score is from -0.281 (for the worst health state, score of 5 for all categories) to 1 (for the best health state, score of 1 for all categories).	Baseline to 6 months
Change in EQ-5D-5L Visual Analogue Scale (VAS) Score	VAS score is obtained using vertical 20-cm visual analogue scale with the top value of 100 labelled as 'the best health you can imagine' and the bottom value of 0 labelled as 'the worst health you can imagine'.	Baseline to 6 months
Percentage of Participants With Adverse Events (AEs)	An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including a clinically significant abnormal finding in laboratory tests or other diagnostic procedures), symptom, or disease temporally associated with the use of a drug, without any judgment about causality.	From first dose until 30 days after the last dose of study drug, or approximately 38 months
All-Cause Mortality	All-cause mortality in the first 30 days and first 60 days after the start of treatment divided by the total number of participants receiving at least one dose of study treatment.	From the first dose until 60 days after the first dose of study drug

Collaborators and Investigators

• Sponsor: Astex Pharmaceuticals, Inc.
• Investigators: Study Director: Harold N Keer, MD, PhD, Astex Pharmaceuticals, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): March 16, 2017
• Primary Completion (Actual): January 20, 2020
• Study Completion (Actual): June 1, 2020

Study Registration Dates

• First Submitted: September 28, 2016
• First Submitted That Met QC Criteria: September 28, 2016
• First Posted (Estimated): September 30, 2016

Study Record Updates

• Last Update Posted (Actual): May 25, 2023
• Last Update Submitted That Met QC Criteria: May 1, 2023
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Keywords: AML, acute myeloid leukemia, guadecitabine, SGI-110, Phase 3
• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Antineoplastic Agents; Guadecitabine
• Other Study ID Numbers: SGI-110-06

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No